200
Participants
Start Date
September 15, 2019
Primary Completion Date
December 1, 2021
Study Completion Date
June 22, 2022
BioMime™ Morph - Sirolimus Eluting Coronary Stent System
Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
Xience family Everolimus Coronary Stent Systems
Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio \[BioMime™ Morph (n=133) vs. XIENCE family (n=67)\].
Lead Sponsor
Meril Life Sciences Pvt. Ltd.
INDUSTRY